



A biosimilar is a biologic medical product that is highly similar to another U.S. Food and Drug Administration (FDA)-approved biological medicine and has **no clinically meaningful differences in terms of safety and effectiveness.**

As of September 2021, the **FDA has approved 30 biosimilars, with 21 products available to patients across a number of costly and difficult-to-treat illnesses**—from cancer to autoimmune diseases.

## BUT WHAT DOES THE PROMISE OF BIOSIMILARS MEAN FOR YOU?

### EFFECTIVE TREATMENT OPTIONS



The FDA has robust, science-based standards for the review and approval of biosimilar medicines before they get to patients—learn more [here](#).

### MORE AFFORDABLE TREATMENT OPTIONS



Biosimilars have the potential to reduce costs and have already done so across several therapeutic areas where natural competition is taking place between products—learn more [here](#).

### EDUCATION TO FOSTER CONFIDENCE



Biosimilar education for healthcare providers, patients, payers, and employers is key to supporting biosimilar acceptance and use—learn more [here](#).

### CUTTING EDGE INNOVATION IS VITAL



Protecting intellectual property and life-saving innovation is essential to a healthy marketplace—learn more [here](#).

Please find additional information on [AmgenBiosimilars.com](https://www.amgen.com/biosimilars) and [the FDA website](https://www.fda.gov).